生物疗法和银病恶性风险:一个回顾性队列研究
Saori Takamura1, Souichiro Saito1, Sora Sugai1
1Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
The Journal of dermatology
|September 9, 2025
概括
与局部治疗相比,牛皮的生物治疗显著降低了恶性瘤的风险. 癌症家族史可能会增加生物药物患者的风险,强调个性化治疗方法.
科学领域:
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮是一种慢性炎症状况,越来越多地使用生物疗法.
- 生物治疗的长期安全性,特别是关于恶性瘤风险的安全性,需要进行彻底的调查.
研究的目的:
- 为了比较接受连续生物治疗的牛皮病患者的恶性瘤发病率与局部单一治疗.
- 为了确定生物治疗队列中恶性瘤的潜在风险因素.
主要方法:
- 446名牛皮患者的回顾性分析 (2010年5月至2023年3月).
- 使用Kaplan-Meier方法和Cox比例危险回归与倾向得分调整的恶性瘤发病率的比较.
- 生物治疗组内的子组分析,以确定额外的风险因素.
主要成果:
- 总体恶性瘤发病率为11.2%,生物组为4.4%,局部组为18.2% (p < 0.0001).
- 生物治疗与显著降低恶性瘤风险相关 (HR:0.316; p = 0.0211).
- 恶性瘤家族病史是生物治疗患者恶性瘤的独立风险因素 (HR:9.01;p < 0.05).
结论:
- 在牛皮患者中,与局部单一治疗相比,生物疗法显示恶性瘤的风险明显较低.
- 患有恶性瘤的家族病史是使用生物制剂治疗的患者患癌症的重要风险因素.
- 个性化癌症风险评估对于在牛皮管理中选择治疗至关重要.
更多相关视频
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Skin Cancer
5.7K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.7K


